Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bismuth(III) oxide is an inorganic chemical compound that serves as the primary radiopacifier in White Mineral Trioxide Aggregate (WMTA), a bioactive material used extensively in endodontic dentistry for procedures such as pulp capping, apexification, and root-end filling (Camilleri, 2007). Its inclusion in WMTA (typically comprising approximately 20% of the powder weight) is essential for providing the necessary radiographic contrast to distinguish the material from surrounding dental tissues like dentin and bone (PubChem CID 14777). While it is effective for diagnostic visualization, bismuth oxide is not a traditional therapeutic target such as a receptor or enzyme; instead, it is a functional additive within a medical device. Research has identified bismuth oxide as the principal cause of tooth discoloration associated with WMTA, as it can react with light, blood, or dental collagen to form dark precipitates (Marciano et al., 2014; Vallés et al., 2013). Beyond its physical properties, it may contribute to the antimicrobial environment of the dental cement, although its primary role remains the provision of radiopacity for clinical monitoring.
Bismuth(III) oxide functions as a radiopacifying agent by absorbing X-ray radiation due to the high atomic number of bismuth, which allows for the visualization of dental materials on radiographs (Camilleri, 2007). It is not a biological target but is incorporated into the mineral matrix of dental cements to provide diagnostic contrast; it may also contribute to the high pH and antimicrobial properties of the material during the hydration process (Marciano et al., 2014).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bismuth(III) oxide (Bi2O3).